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Abstract
Copy Number Variants (CNVs) are now recognized as playing a significant role in complex disease etiology. Age-related
macular degeneration (AMD) is the most common cause of irreversible vision loss in the western world. While a number of
genes and environmental factors have been associated with both risk and protection in AMD, the role of CNVs has remained
largely unexplored. We analyzed the two major AMD risk-associated regions on chromosome 1q32 and 10q26 for CNVs
using Multiplex Ligation-dependant Probe Amplification. The analysis targeted nine genes in these two key regions,
including the Complement Factor H (CFH) gene, the 5 CFH-related (CFHR) genes representing a known copy number
‘‘hotspot’’, the F13B gene as well as the ARMS2 and HTRA1 genes in 387 cases of late AMD and 327 controls. No copy
number variation was detected at the ARMS2 and HTRA1 genes in the chromosome 10 region, nor for the CFH and F13B
genes at the chromosome 1 region. However, significant association was identified for the CFHR3-1 deletion in AMD cases
(p=2.38610
212) OR=0.31, CI-0.95 (0.23–0.44), for both neovascular disease (nAMD) (p=8.3610
29) OR=0.36 CI-0.95 (0.25–
0.52) and geographic atrophy (GA) (p=1.5610
26) OR=0.36 CI-0.95 (0.25–0.52) compared to controls. In addition, a
significant association with deletion of CFHR1-4 was identified only in patients who presented with bilateral GA (p=0.02)
(OR=7.6 CI-0.95 1.38–41.8). This is the first report of a phenotype specific association of a CNV for a major subtype of AMD
and potentially allows for pre-diagnostic identification of individuals most likely to proceed to this end stage of disease.
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Introduction
Age-related Macular Degeneration (AMD) is a complex disease
associated with multiple gene and environment interactions [1]. It
is also the leading cause of vision loss in the western world and
ranks third among global causes of visual impairment [2]. Rapid
progress in identifying genetic risk factors for AMD susceptibility
has been made over the last few years including the identification
of two major loci at chromosome 1q32 and 10q26. Whilst these
two loci appear to account for the majority of genetic susceptibility
in Caucasian populations with AMD, the mechanisms behind
their involvement in AMD development and progression are still
incompletely understood [3].
Copy Number Variations (CNVs) (deletions and duplications
.1000 bp) have recently been shown to have an important role in
complex disease phenotypes, most notably in autoimmune related
disorders such as Psoriasis [4], Rheumatoid Arthritis [5], Systemic
Lupus Erythematosus (SLE) [6] and Atypical Hemolytic Uremic
Syndrome (aHUS) [7]. A great proportion of CNVs are enriched
towards secreted, olfactory and immunity proteins [8] and it is well
known that regions flanked by duplicons (regions of high sequence
similarity .95% and a at least 10kb in length) are ‘‘hotspots’’ for
CNV and thus more likely to undergo recurrent rearrangements
due to non-allelic homologous recombination (NAHR) [9].
Analysis of the Regulators of Complement Activation (RCA)
alpha block located on chromosome 1q32 that contain the CFH,
CFH related 1–5 and F13B genes and analysis of the chromosome
10q26 region containing the ARMS2 and HTRA1 genes has
identified a series of single nucleotide polymorphisms (SNPs)
associated with both risk of, and protection against, AMD [10,11].
It has previously been shown that an 84 kb deletion encompassing
the entire CFHR3 and CFHR1 genes is associated with protection
in AMD [12,13]. This same deletion is inversely associated with
aHUS, thus representing a significant genetic risk factor [14]. Of
the five ancestrally related CFHR genes, CFHR3, CFHR1 and
CFHR4 are flanked by segmental duplicons and re-arrangements
between these duplicons are common but vary in frequency
between ethnicities [15]. At the chromosome 10 locus, the two
genes, ARMS2 and HTRA1 have been extensively screened using
SNPs and inferred SNP haplotypes [11,16], but these genes have
yet to be analyzed for larger structural variation which may impact
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number of individuals has already revealed an insertion/deletion
(indel) polymorphism in the 39UTR (del443ins54) of AMRS2,
showing significant association with increased risk of AMD [17].
On the basis of the genomic architecture of the RCA block and
the as yet unexplored chromosome 10 regions for CNV, we
hypothesized that, in addition to the common CFHR3-1 deletion,
other potential rearrangements encompassing the CFH, CFHR4,
CFHR2, CFHR5, F13B, ARMS2 and HTRA1 genes may contribute
to AMD pathogenesis. Two recent reports of a rare CFHR1-4
deletion further support this notion that other CNVs exist in these
regions [18,19]. To assess this region in more detail we have
applied Two-colour Multiplex Ligation-dependant Probe Ampli-
fication (MLPA), a well established method for detecting
quantitative changes in DNA [20,21] and quantitative polymerase
chain reaction (qPCR) to validate our findings in a cohort of AMD
cases and controls from Australia.
Materials and Methods
Study Design
The study was conducted in accordance with the Declaration of
Helsinki and according to the National Health and Medical
Research Council of Australia’s statement on ethical conduct in
research involving humans, revised in 2000. Written informed
consent was obtained from all individuals, and ethics approval for
the project was provided by the Human Research and Ethics
Committee of the Royal Victorian Eye and Ear Hospital
(RVEEH), Melbourne. The detailed methods of clinical diagnosis
of late AMD as well as control samples has been previously
reported [22]. In brief, this was a prospective study with all
patients recruited from the RVEEH upon attendance at the clinic.
All individuals included in this study were Caucasian of Anglo-
Celtic ethnic background. At the time of recruitment, a standard
risk factor and disease history questionnaire was undertaken, a
clinical examination was performed, a fundus photograph
obtained, and a blood sample collected for DNA analysis. Cases
had a diagnosis of late AMD which consisted of either neovascular
disease (nAMD) or geographic atrophy (GA) whereas control
individuals were included if they had a normal fundus (,10 hard
drusen ,63 mm in size) and no altered macular pigmentation in
either eyes. 268 cases on nAMD, 86 Bilateral GA, 33 unilateral
GA and 327 normal controls were utilized for this study (Table 1).
Cases of nAMD were verified in the clinic on angiography or in
clinical notes from the treating clinician. Cases and controls were
graded using the modified International Classification System for
AMD by two independent graders.
Multiplex Ligation-dependant Probe Amplification
(MLPA)
Probe Design. Two-colour MLPA as described by White et
al. [21] was used to assess CNVs. Probes were designed to each
coding exon of HTRA1 (9 exons) and ARMS2 (2 exons), 17 of the
23 coding exons of CFH and 3 coding exons contained within
F13B. To analyze the CFHR1-5 region 5 probes were positioned
within the 2 flanking segmental duplicons extending from CFHR3
to CFHR4, while another 4 probes were designed within the
remaining CFHR2 and CFHR5 genes (Table S1). To allow for
simultaneous probe amplification, the common ends of each probe
corresponded to the MLPA primers described by Schouten et al.
[20] and the Multiplex Amplifiable Probe Hybridization (MAPH)
primers described by White et al. [23]. The specificity of the probes
was analyzed using the BLAT program at the University of
California Santa Cruz (http://genome.ucsc.edu). Probes were
designed to produce PCR products ranging from 80 base pairs (bp)
to 130 bp. Oligonucleotides were ordered from Sigma Genosys
(www.sigma.genosys.com) with the 59 end of the right hand half-
probe phosphorylated to allow ligation to occur. Probe mixes were
prepared by combining each oligonucleotide so that they were all
present to a final concentration of 4 fmol/ml.
MLPA Reaction. Reagents for the MLPA reaction were
purchased from Fisher Biotec (Australia) with the exception of
MAPH primers that were purchased from Sigma Genosys. The
MLPA reactions were performed according to the method
published by Schouten et al. [20]. Briefly, 250 ng of DNA in a
final volume of 5 ml was denatured at 98uC for 5 minutes, after
cooling at room temperature, 1.5 ml of probe mix and 1.5 mlo f
Hybridization buffer was added to the sample, heat denatured at
95uC for 1 minute followed by hybridization at 60uC for 16 hours.
Ligation was performed at 54uC by adding 32 ml of ligation
reaction, after 15 minutes the enzyme was inactivated by heating
at 95uC for 5 minutes.
Polymerase Chain Reaction (PCR) amplification was carried
out under the following conditions: 1 cycle of 98uC for 1 minute;
35 cycles of 95uC 30 seconds, 57uC 1 minute, 72uC 1 minute; and
1 cycle of 72uC 20 minutes. The PCR reaction was performed in
25 ml.
From each PCR reaction, 1 ml was mixed with 8.8 ml of HIDI
formamide and 0.2 ml of LIZ500 size standard (Applied
Biosystems). Product separation was performed on the ABI 3130
Electrophoresis 16 capillary sequencer (Applied Biosystems).
Data Analysis. Data Analysis was performed using the
GeneMapper Software (Applied Biosystems) and the peak
heights were exported to Microsoft Excel. A ‘‘global’’ or
‘‘population based’’ analysis was implemented whereby
normalization was performed by calculating the sum of all peak
heights from each sample and dividing by the individual peak
heights of each probe [24]. The median was calculated for each
probe which was then divided by each individual probe to
calculate the number of copies of each exon. Thresholds for
deletions and duplications were set at below 0.75 and above 1.25
respectively. All samples were tested at least twice.
Quantitative PCR (qPCR)
To verify the results of MLPA, a qPCR assay was designed for
the CFHR3 and CFHR4 genes using FOXP2 as the control gene
Table 1. Characteristics of the study population: Age and Gender Distribution of AMD Cases and Controls.
Unilateral GA (n=33) nAMD (n=268)
Bilateral Geographic
Atrophy (n=86) Total Cases (n=387) Controls (n=327)
Female n (%) 15 (45) 173 (64) 59 (68) 248 (64) 182 (47)
Age (SD) 696(10.2) 766(7.7) 716(9.6) 746(8.6) 716(7)
doi:10.1371/journal.pone.0035255.t001
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was conducted in triplicate using 25 ng of DNA, PCR reactions
were performed using 7.5 mlo f2 6 Bioline Syber Green Master
Mix (www.bioline.com), 0.5 ml of 10 pmol/ml primers and 5 mlo f
DNA in a 15 ml reaction. qPCR cycling protocol consisted of 95uC
for 3 minutes; 40 cycles of 95uC for 5 seconds, 63uC for 5 seconds,
72uC for 10 seconds. Copy number calculations were performed
using the Delta-Delta CT method and average copy number was
set at 2 [25].
Quantitative Multiplex PCR of Short Fluorescent
Fragments (QMPSF)
To verify results of CFH exon 18 we employed QMPSF analysis
as described by Casili et al. [26]. Briefly, primers were designed to
flank CFH exon 18. The primers used were chimeric and had 59
extensions of CGTTAGATAG on the forward primer or
GATAGGGTTA on the reverse primer. All forward primers
were 59 labeled with 6-FAM. An additional primer pair amplifying
the HMBS gene located on chromosome 11 was used as an
internal control as described by Saugier-Veber et al. [27]. Primer
Pairs are listed in the Table S4, PCR reactions were performed as
previously described using a modified PCR protocol to allow for
quantitative conditions [27].
Statistics
Chi Square analysis, Fisher’s exact test and deviations from
Hardy-Weinberg Equilibrium (HWE) was performed using
PLINK software v1.07 [28]. All genotypes were in HWE
(p=.0.001). Logistic regression models were constructed to
determine the odds ratio (OR) and 95% confidence intervals (CI
0.95) for AMD cases while conditioning on the rs1061170 SNP in
the CFH gene, the rs10490924 SNP in the LOC387715 gene and
the rs11200638 SNP in the HTRA1 gene after adjustment for age,
gender and smoking. Logistic regression and conditional analysis
was performed using PLINK v1.07.
Results
Patient Samples
A total of 714 individuals consisting of 387 late stage AMD cases
with either nAMD (n=268) or bilateral GA (n=86) or unilateral
GA (n=33) and controls (n=327) without AMD were included in
the CNV analysis. The average age of all cases at examination was
74 years with those having nAMD having a mean age of 75 years
and those having GA a mean age of 71 years. The average age of
control participants was 71.4 years. Male to female ratios were
247/136 (64% vs 36%) in cases and 182/145 (53% vs 47%) in
controls.
Probe Design
Copy number analysis was performed on genes from two well
established AMD associated genomic loci, targeting seven genes
on chromosome 1q32 (CFH, CFHR1, CFHR2, CFHR3, CFHR4,
CFHR5, F13B) and two genes on chromosome 10q26 (ARMS2 and
HTRA1) (Figure 1). The probe coverage on chromosome 1
extended almost 0.5 mega base (Mb) from exon 1 of the CFH gene
to the final exon of the F13B gene, while on chromosome 10 the
genomic coverage was 60 kilo bases (kb) extending from the first
exon of the ARMS2 gene to the final exon of the HTRA1 gene. Not
all coding exons within the CFH gene were amenable to MLPA
probe design due to the extensive homology existing between the
CFH and the CFHR1-5 genes. Reliable MLPA probe designs could
not be achieved for exon 7 and exons 20–23 of the CFH gene, but
nevertheless we were able to design probes for the majority of the
CFH gene covering 17/22 its exons. Reliability of probe designs
was calculated by assessing the standard deviation (SD) of the
normalized probe ratio (1.0 indicating CN of 2) for all 43 probes in
Figure 1. Schematic Representation of Chromosome 1q32 and Chromosome 10q26. (A) Chromosome 1q32 showing a 419 kb region
containing the CFH, CFHR1-5 and F13B genes. The vertical lines represent exons in each of the genes. The horizontal arrows at the top represent the
direction of transcription. The numbers (top) represent the MLPA probe positions across each of the genes. (B) Chromosome 10q26 show a 60 kb
region containing the ARMS2 and HTRA1 genes. The horizontal arrows at the top represent the direction of transcription. The numbers represent the
MLPA probe positioning in each of the coding exons (vertical bars) across these genes.
doi:10.1371/journal.pone.0035255.g001
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reliable performance of all probe designs (Table S1).
Detection of re-arrangements on 1q32 and 10q26
MLPA analysis did not reveal the presence of any large re-
arrangements encompassing either the ARMS2 or HTRA1 genes at
chromosome 10q26 in either cases or controls. Similarly the CFH,
CFHR2, CFHR5 and F13B genes did not show evidence of CNVs.
Analysis of CFH exon 18, appeared to indicate the presence of a
heterozygous deletion. Further analysis of the ligation site used to
detect this deletion revealed a SNP (rs35292876) identified from
recent 1000 genomes data (http://genome.ucsc.edu) likely leading
to disturbance of the ligation site and thus giving the appearance of
a heterozygous deletion. Confirmation that the exon was indeed
only present as two copies was made using Quantitative Multiplex
PCR of Short Fluorescent fragments (QMPSF) where primers
were designed that flanked the exon (Table S4). Within the
remaining CFHR3, CFHR1 and CFHR4 genes, we detected 6
different combinations of re-arrangements, the common CFHR3-1
deletion (homozygous and heterozygous), the CFHR1-4 deletion,
deletion of CFHR1 with reciprocal duplication as well as deletion
of CFHR3 (Figure 2).
Analysis of CNV’s and late AMD
Analysis of the common CFHR3-1 deletion demonstrated its
association with protection in AMD being present in a total of
32.8% of controls compared to 13.75% of cases (p=2.38610
212)
OR=0.31, CI-0.95 (0.23–0.44) (Table 2). The homozygous
deletion was almost 10 fold more frequent in controls (5.8%)
compared to cases (0.75%), whereas in the heterozygous state it
was 2 fold more frequent in controls (27%) compared to cases
(13%). Subtype analysis in both end stage nAMD and GA showed
that the deletion was protective in both subtypes at (p=8.3610
29)
OR=0.36 CI-0.95 (0.25–0.52) and (p=1.5610
26) OR=0.36 CI-
0.95 (0.25–0.52) (Table 2). We performed logistic regression
analysis adjusting for gender, age, smoking and conditioning on
the Y402H (rs1061170) polymorphism of the CFH gene. A
statistically significant association remained after adjusting for
these confounders (1.34610
25) OR=0.40 CI-0.95 (0.27–0.60)
(Table 3), consistent with previous reports [19,29,30]. We also
conditioned on other CFH SNPs rs800292 and rs1061147 and
found the same result (data not shown). Conditional analysis on
two of the high risk SNPs in the chromosome 10 region
rs10490924 and rs11200638 also showed a statistically significant
association with protection from AMD (3.2610
29) OR=0.28 CI
0.95 (0.19–0.43) (Table 3). Analysis of the rare CFHR1-4 deletion
showed that while the deletion was not associated with risk or
protection in late AMD cases as a whole (p=0.46), stratification by
subtype revealed a statistically significant association with risk of
cases with bilateral GA (p=0.02) OR=7.6 CI 0.95 (1.38–41.8).
Analysis in 327 controls showed that the frequency of the deletion
was below ,1% compared to 4.7% in bilateral GA. We observed
no significant difference in the nAMD subtype (p=1.0). The other
three re-arrangements detected in the CFHR genes were too rare
to infer any statistical significance, consistent with previous reports
[31].
Discussion
We have carried out a comprehensive analysis of copy number
variation in nine genes from the two most significantly AMD risk
associated loci. Identification of the rare heterozygous CFHR1-4
deletion appears significantly associated with risk of bilateral GA,
being 6 times more frequent in this late phenotype compared to
that of nAMD. Interestingly this deletion is present in only 0.74%
of nAMD cases, but 4.7% in bilateral GA, suggesting that the
deletion may contribute to a different pathophysiological process
associated with the bilateral GA phenotype (p=0.03). We also
provide further evidence for the protective role of the CFHR3-1
deletion in AMD, with the homozygous deletion being present in
5.4% of control samples compared to only 0.75% of cases. Three
other rare re-arrangements in CFHR1 and CFHR3 were also
identified in two control samples and one case including a
heterozygous deletion of CFHR3 and a heterozygous deletion and
a duplication of CFHR1. Analysis of the coding exons of the CFH
gene, did not reveal any contiguous or non-contiguous CNVs
extending from the CFHR region. Similarly, analysis of the F13B
gene in a subset of 100 cases and 100 controls did not show
evidence of CNVs. The ARMS2 and HTRA1 genes also showed no
evidence of CNVs, suggesting that the ARMS2 indel (del443ins54)
located in the promoter region may represent the only major and
relatively large structural variant at this locus.
Population based frequencies of the CFHR3-1 and CFHR1-4
deletions show evidence of population stratification across multiple
ethnicities [12,32]. A study by Hageman et al. showed that the
frequency of the homozygous CFHR3-1 deletion in Africans was as
high as 16% compared to 7% in Hispanics, 5% in Caucasians, and
only 2% in Asians [12]. Data from the 1000 genomes project [32]
also supports this finding indicating that combined analysis of
heterozygous and homozygous CFHR3-1 deletions are present in
approximately 50% of Africans compared to 25% in Europeans
and less that 10% in Asians [32]. The European frequency is
comparable to the combined analysis of homozygous and
heterozygous deletions at 32.8% reported here [12,18]. The
CFHR3-1 deletion frequency within African populations may also
account for the reduced prevalence of AMD within this population
compared to Europeans [33] although it cannot be ruled out that
this invariably reflects an earlier age of mortality in this group.
Nevertheless it cannot be discounted that the presence of this
CNV is positively selected given that these genes have recently
been identified as functionally important in complement regula-
tion [29]. Analysis of the rare CFHR1-4 deletion in our Caucasian
control population showed the frequency to be ,1%. This
frequency was similar to data from the 1000 genomes project
which showed no evidence of this CNV in Caucasians and below
5% frequency in Africans and Asians (n=159) [32].
Analysis of the CFHR3-1 deletion in our study found similar
frequencies to those described previously of homozygous deletions
in cases (0.8%–1.2%) and controls (4.9%–5.2%), similarly
heterozygous deletions between cases (17%–18%) and controls
(22%–27%) [12,31]. Like others [12,13], we also identified a clear
gene dosage effect between CFHR3-1 heterozygous and homozy-
gous deletion samples where individuals with homozygote
deletions conferred higher protection from AMD. A study by
Fritsche et al. demonstrated that homeostatic balance between
CFHR1, CFHR3 and CFH determines complement activity and
influences inflammation [29]. CFHR3 and CFHR1 compete with
CFH for C3b binding, the loss of two complement regulators from
the homozygous deletion of CFHR3/1 results in increased binding
of CFH to C3b thereby regulating CFH mediated complement
activity [29]. They also showed this affect was independent of the
Y402H and A473A polymorphism of the CFH gene further
confirming that this CNV is functionally relevant in AMD
pathogenesis. Consistent with these findings and others
[19,29,30], we also showed that this effect is independent of
Y402H. Studies attempting to verify the independent effects of this
deletion have shown that while the statistical strength is mitigated
upon conditioning of several highly associated SNPs within CFH,
Copy Number Variants in AMD
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report by Hughes et al. suggested that the reduction in P value, was
a reflection on allele frequency, rather than affect size, as the OR’s
between rs2274700 and rs10737680 confer almost equal effects to
that of the CFHR3-1 deletion (0.37–0.39) [34].
While this manuscript was in preparation three other studies
reported on CNVs in the CFHR1-5 region with AMD [18,19,35].
Sivakumaran et al. [35] reported that an increase CFHR3-1 CN
showed trends towards risk, before conditioning on the most
significant SNPs in CFH. Interestingly, we and others
[12,13,18,29,31] have not detected enrichment of increased
CFHR3-1 copy numbers in AMD cohorts, in fact this appears to
be a rare event. In contrast to our data, and others, Sivakumaran et
al. also reported that additional copies of CFHR1-4 appeared to
confer risk to AMD, suggesting that the deletion conferred
protection [35]. The reciprocal duplication of CFHR1-4 appears to
also be a rare event in Africans, Asians and European control
populations [32], and was not detected in two subsequent studies
of AMD cases and controls [18,19]. This may be a reflection of
ethnic differences between the cohorts or the methods used to
genotype the re-arrangements at the CFHR1-5 region. Several rare
re-arrangements, the majority of which, residing in intergenic
regions between the CFHR1-5 genes has been reported [35]. De-
novo events affecting several exons within CFH were detected
within samples from African ancestry. In support of our data, these
changes were not detected among Caucasian samples suggesting
that re-arrangements within CFH are rare events, unlikely to have
an impact on AMD pathogenesis in individuals of European origin
[35].
While there appears to be overwhelming consensus in relation
to the association of the CFHR3-1 deletion and protection from
AMD, the same cannot be said for the rare CNV of CFHR1-4.
Two recent studies found no significant association with this
variant and AMD [18,19]. The frequency of this deletion appears
to fluctuate depending on the cohort and methodologies used for
genotyping. In addition, the deletion and or reciprocal duplication
have not been found to be in linkage disequilibrium (LD) with
flanking SNP markers [18,35], thus must be genotyped directly.
Both studies by Sawitzke et al. and Sivakumaran et al. used samples
from the Age Related Eye Disease Study (AREDS) but appeared
Figure 2. Peak Patterns and Scatter Plots. Scatter plots representing 5 different CNV re-arrangements detected in the CFHR3, CFHR1 and CFHR4
genes in our sample cohort. Probes targeting the CFH gene are represented in black, probes targeting the CFHR1-5 and F13B genes are represented in
blue and probes corresponding to the ARMS2 and HTRA1 genes are represented in red. The x axis describes each probe number which corresponds to
the numbered probe list in Table S1. The y axis represents normalized probe ratios relative to a two copy locus (Normal range 0.75–1.25). The scatter
plots describe (A) a heterozygous deletion of CFHR3-1, (B) a homozygous deletion of CFHR3-1, (C) a heterozygous deletion of CFHR1-4, (D) a
heterozygous deletion of CFHR3, (E) heterozygous deletion of CFHR1 (F) heterozygous duplication of CFHR1.
doi:10.1371/journal.pone.0035255.g002
Copy Number Variants in AMD
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These findings of differing copy number changes in two sub
populations of AREDS individuals cannot be easily explained.
One explanation is the potential for admixture in the population
and it would be interesting if the two sub cohorts were assessed for
this effect. Ethnicity information was not reported in either of the
Sawitzke or Sivakumaran studies. Another potential explanation is
that two differing methodologies used to analyze this region
(qPCR and array CGH) may have led to some methodological
biases between the two studies [19,35].
Interestingly, several studies of CNVs in other diseases have
shown similar conflicting data. Lower copy number of the FC
Gamma Receptor 3B (FCGR3B) gene has been shown to be
associated with Rheumatoid Arthritis (RA) [5], while other studies
have failed to replicate this association [25,36]. Similarly, analysis
of CC Chemokine Ligand 3-like 1 (CCL3L1) in HIV AIDS
susceptibility has found evidence of lower copy number and HIV
susceptibility [37], while others have found no association [38,39].
It remains unclear as to whether accurate assessment of CNVs,
population sub structure, admixture, or whether small changes in
detected frequencies of rare CNVs in cases and controls affected
by sample size are the main contributing factors to the
reproducibility of these associations.
Functionally the CFHR4 gene has been shown to be important
in complement regulation [40]. CFHR4 protein binds to a
pentameric form of C-reactive protein (pCRP) (different from
the monomeric CRP bound by CFH) and recruits pCRP to the
surface of necrotic cells enhancing removal of necrotic cells
directly or facilitating C1q binding and complement activation
[41]. In addition, it has been proposed that CFHR4 limits
inflammation by enhancing the co-factor activity of CFH and
enhancing complement deposition by CRP binding which helps
phagocytic clearance of microbes and necrotic cells in inflamed
tissues [40]. If CFHR4 regulates complement activation and
opsonization on biological surfaces via interaction with pCRP
[40], then potentially a deletion of this gene would lead to reduced
pCRP binding and thus limit its capacity to inhibit inflammation
leading to enhanced disease. A similar hypothesis has also been
suggested for the CFH gene by Laine et al. [42] whereby binding
affinity of CRP for CFH was influenced by the Y402H
polymorphism. It was suggested that impaired binding of CRP
to CFH reduced the ability for CFH to modulate inflammation
[42]. Furthermore, no individuals in the current study presented
with both the CFHR3-1 and CFHR1-4 deletions on both alleles as
described previously [14]. As these genes represent a functionally
different component to complement regulation, it suggests that
homeostatic balance between CFH, CFHR3, CFHR1 and CFHR4
is necessary to maintain regulation of complement activation.
Typically, studies analyzing the CFHR1-5 gene cluster have
incorporated an MLPA based approach [13,14,18,29,31]. MLPA
utilizes a ligation step to join two adjacent oligonucleotide probe
sequences together after hybridization [20]. This step provides
increased sensitivity to distinguish between two highly homologous
sequences [43]. However, an unsuspected polymorphism near the
ligation site of the two MLPA oligonucleotides can hamper accurate
determination of CNV regions [44]. In most primer probe based
assays, a polymorphism can disturb primer binding enough to give
the appearance of a deletion [45]. In this case a deletion detected
with a single probe should always be confirmed via an alternative
method. With this in mind we implemented three methods of CNV
detection through the use of MLPA, QMPSF and qPCR.
Data from Kubista et al. previously identified a heterozygous
deletion of CFHR2 at a frequency of less than 1% [18]. We and
others [19,35] did not detect this deletion in our respective
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polymorphism on the ligation site for the CFHR2 MLPA probe
used by Kubista et al. [18]. Sequence analysis revealed a
polymorphism C.T (rs72736421) directly on the ligation site
which is likely to disturb the probe binding sufficiently to give the
appearance of a heterozygous deletion. We identified similar
polymorphisms for probes used to analyze CFH exon 18
(rs115722139) and CFH intron 1 (rs77837548), although these
polymorphisms were further away from the ligation site, 8 bp and
3 bp respectively [18]. In the case of the CFH exon 18 MLPA probe
used in this study, analysis of the ligation site showed a
polymorphism C.T (rs35292876) directly on the ligation site
which would explain the presence of an apparent deletion that was
initially detected using this technique but yet could not be detected
in confirmatory studies using QMPSF (Table S3). The polymor-
phism was not identified during the original probe design and was
only identified following release of the first draft of the 1000
genomes data.
Our understanding of CNVs and the role that they play in
complex disease is likely to increase substantially in the next few
years, especially with recent advancements in next generation
sequencing and array based Comparative Genome Hybridization
[46,47]. Of continuing interest is the apparent reversal of
associations seen in seemingly unrelated complex diseases to what
are essentially identical copy number variants. For example,
studies of the RCA alpha block encompassing CFH and CFHR1-5
genes have shown associations with AMD, aHUS, Membrano-
proliferative Glomerulonephritis [48] and SLE. Curiously, the
CFHR3-1 deletion has now been shown to be associated with risk
in aHUS [14] and SLE [49] but protection in AMD [12]. The
same study in aHUS individuals also showed that combined
deletion of CFHR3-1 and CFHR1-4 on both alleles is associated
with risk of aHUS [14]. Similarly studies analyzing the beta
defensin gene cluster have shown that while increased beta
defensin copy number (.5 copies) is associated with psoriasis, low
copy numbers (,4 copies) are associated with Crohn’s Disease
[50,51]. Further investigation into the functionality of these CNV
regions is required to assess their impact on complex disease
pathogenesis. These findings may indicate a dosage response
mechanism or differing action depending on the tissue type.
Our finding that the rare CFHR1-4 deletion is associated with
risk of bilateral GA may have important research and clinical
implications, particularly as our current knowledge regarding how
progression of AMD occurs towards the two late stage phenotypes
of GA and nAMD is currently limited. While this is an interesting
finding, we are cautious about reporting associations of rare
variants especially given the conflicting data from three other
reports. Replication in larger populations would strengthen the
argument that the findings reported here are reproducible before
any definitive conclusions can be drawn concerning a clinically
relevant association between this variant and AMD.
Our data represents a comprehensive study of copy number
variation in genes associated with AMD. Our cohort was collected
from a single centre with all cases being seen by a small number of
retinal specialists. The phenotype information was well character-
ized with ethnicity information collected. In summary we
demonstrate that the relevant copy number ‘‘hotspot’’ in AMD
lies in the region encompassing the CFHR3, CFHR1 and CFHR4
genes. These findings support the idea that CNVs do impart a likely
functionalroleinAMDpathogenesisthroughgenedosage effectson
genes regulating the complement cascade. Given that many copy
number polymorphisms (CNPs) are poorly tagged by SNPs, and are
likely to exert their own independent effects, a combined effort
analyzing all classes of genetic variation such as SNPs, Indels and
CNVs is likely to lead to a greater understanding of AMD
pathogenesis. Given the substantial number of people affected by
AMD this finding if replicated would greatly enhance our ability to
predict which patients are most likely to go on to develop GA and
thereby offer specific treatments targeted to such a group.
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